New combo therapy may shield diabetic kidneys from damage
NCT ID NCT07586371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an SGLT2 inhibitor to standard ARB therapy better reduces protein in the urine (a sign of kidney damage) in diabetic patients without high blood pressure. Sixty adults aged 30-60 with diabetes and microalbuminuria will receive either ARBs alone or ARBs plus an SGLT2 inhibitor. The goal is to see which approach more effectively lowers proteinuria and slows kidney disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faisalabad Medical University
Faisalābad, Punjab Province, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Prescribing food: could a diet of medically tailored meals tame diabetes?
- Alexa, teach me about diabetes: smart speaker trial aims to improve blood sugar in older adults
- Do GLP-1 users skip strength training? new survey aims to find out
- Will a sticky patch stay put? study tests future pump design on kids